study period (median follow-up, 15 months [IQR, 4 months to 4.2 years]); all were attributed to the patients’ malignancies. Patient Characteristics According to Esophagitis Risk Factors We compared the clinical characteristics of patients with risk
Search Results
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis
Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang
Long-Term Outcomes of Myeloid Growth Factor Treatment
Gary H. Lyman and David C. Dale
of AML/MDS increased significantly with the cumulative dose of epirubicin. In multivariate regression analysis, the cumulative doses of epirubicin and cyclophosphamide, but not of G-CSF, were independent risk factors for AML/MDS. Because G-CSF enables
NCCN Task Force Report: Breast Cancer in the Older Woman
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
point system for 4-year mortality risk: 0 to 5 points: 4% or less; 6 to 9 points is 15%; 10 to 13 points is 42%; and 14 or more points is 64%. Table 4. Independent Risk Factors for 4-Year Mortality The Adjuvant! Online program provides estimates of the
Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar
cancer. BMC Cancer 2006;6:194; and Elkum N, Dermime S, Ajarim D, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 2007;7:222. Based on international
Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments
J. Matt McCrary, David Goldstein, Terry Trinh, Hannah C. Timmins, Tiffany Li, Jasmine Menant, Michael Friedlander, Craig R. Lewis, Mark Hertzberg, Siobhan O’Neill, Tracy King, Annmarie Bosco, Michelle Harrison, and Susanna B. Park
determine the additive effect of the significant independent variables identified in the stepwise model, each symptom or clinical abnormality represented by the independent variables was classified as a risk factor. Continuous variables were converted into
HSR21-047: Tumor Lysis Syndrome Risk Analysis in a US Community Oncology Setting: A Retrospective Observational Study in Integra Connect Network
Kaustav Chatterjee, Edward Drea, Robert Smith, Mei Xue, Hunter Lambert, Jeffrey Scott, Sorena Nadaf, Simon Blanc, Prateesh Varughese, and John Verniero
following chemotherapy [1] . However, no real-world data has been published that quantifies TLS risk factors by cancer type. Methods: The Integra database of 17 community oncology accounts was queried for patients ≥18 years of age having a TLS ICD10 code
Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™
-induced thrombocytopenia (CIT) in non–small cell lung cancer (NSCLC) and data in Chinese patients is sparse, we performed a study on gemcitabine-based CIT in Chinese patients with NSCLC. In this study, we examined the main risk factors in this patient population with the
Evolution of Radiation Therapy Within the German Hodgkin Study Group Trials
Hans Theodor Eich, Jan Kriz, and Rolf-Peter Müller
such as the definition of early-favorable, early-unfavorable, and advanced stages, and more specific, risk-adapted treatment strategies. Early-Favorable HL Extension of disease is still the most important risk factor. As reported by the Stanford
Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease
Manish A. Shah and David P. Kelsen
emerged in epidemiologic studies over the past several decades: gastric cardia/gastroesophageal junction (GEJ) tumors. 6 , 7 Table 1 provides a summary of commonly identified risk factors for the development of gastric cancer categorized by disease
Basal Cell and Squamous Cell Skin Cancers: NCCN Guidelines Updates Based on Risk Status
Presented by: Jeremy Bordeaux
, history of radiation therapy (RT), histologic subtype, and whether there is perineural invasion should be considered. Figure 1. Stratification to determine treatment options for local BCC based on risk factors for recurrence. NCCN Clinical Practice
